<doc>
  <docmeta id="113hr4494ih">
    <bill congress="113" type="hr" number="4494" version="ih"/>
    <revision size="18803" annotations="0" status="complete" id="4" commit-time="2014-05-02T19:21:11Z" committer="mbohmer" doc="113hr4494ih/4.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H285C87E1CA204B8683B6B61A229FDB42" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 4494 IH: Regenerative Medicine Promotion Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-04-28</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4494</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140428">April 28, 2014</action-date>
			<action-desc>
        <sponsor name-id="D000197">Ms. DeGette</sponsor> (for herself and <cosponsor name-id="P000594">Mr. Paulsen</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To launch a national strategy to support regenerative medicine through funding for research and
			 commercial development of regenerative medicine products and development
			 of a regulatory environment that enables rapid approval of safe and
			 effective products, and for other purposes.</official-title>
	</form>
	<legis-body id="H2C4EEFC258C04F66A9B7D5F0B6CA07D9" style="OLC">
		<section id="H16C96D624D844B8893CCDE481CA51275" section-type="section-one">
      <enum>1.</enum>
      <header>Short title; table of contents</header>
			<subsection id="H12DD6D8B062D4931B08E982F151F69E3">
        <enum>(a)</enum>
        <header>Short title</header>
        <text>This Act may be cited as the <quote>
            <short-title>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Regenerative Medicine Promotion Act of 2014" proposed="true">Regenerative Medicine Promotion Act of 2014</cato:entity-ref>
            </short-title>
          </quote>.</text>
			</subsection>
      <subsection id="HCCAE9B16F7C6454EBE4BDC212D7AECD3">
        <enum>(b)</enum>
        <header>Table of contents</header>
        <text>The table of contents of this Act is as follows:</text>
				<toc container-level="legis-body-container" lowest-bolded-level="division-lowest-bolded" lowest-level="section" quoted-block="no-quoted-block" regeneration="yes-regeneration">
					<toc-entry idref="H16C96D624D844B8893CCDE481CA51275" level="section">Sec. 1. Short title; table of contents.</toc-entry>
					<toc-entry idref="HF655A93109FB4B3BADCAD6C369DA8E28" level="section">Sec. 2. Findings.</toc-entry>
					<toc-entry idref="H4CA54209D99A4FC69A00AAF960A80027" level="section">Sec. 3. Report on ongoing Federal programs and activities regarding regenerative medicine.</toc-entry>
					<toc-entry idref="H929EFFD38A094CD0AD2C9A7FB68CC33D" level="section">Sec. 4. Establishment of Regenerative Medicine Coordinating Council.</toc-entry>
					<toc-entry idref="H1E896A123DE44DCFA432F5BEFEBAFEB0" level="section">Sec. 5. Grants for basic or preclinical research into regenerative medicine.</toc-entry>
					<toc-entry idref="HF8889E1FCC364DF2AC7C5688D87FF3BF" level="section">Sec. 6. Grants for development of drugs, biological products, medical devices, and biomaterials for
			 use in regenerative medicine.</toc-entry>
					<toc-entry idref="HBD6A79CC31584D5BB62A3DB046B1AD4D" level="section">Sec. 7. Supporting innovation in regenerative medicine through cures acceleration network.</toc-entry>
					<toc-entry idref="H04247BCD794341439A28BE6726202C7A" level="section">Sec. 8. Funding for Food and Drug Administration research.</toc-entry>
				</toc>
			</subsection>
    </section>
    <section id="HF655A93109FB4B3BADCAD6C369DA8E28">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> finds the following:</text>
			<paragraph id="H0222EF1E4F26422398CBE71F42020F59">
        <enum>(1)</enum>
        <text>Regenerative medicine has the potential to treat many chronic diseases, promote economic growth,
			 and reduce health care spending in the United States.</text>
			</paragraph>
      <paragraph id="H2557DB8BAA5D45A8A876289BC0205380">
        <enum>(2)</enum>
        <text>Regenerative medicine products have already successfully treated numerous health conditions, and
			 have the potential to provide cures, treatments, and diagnostics for a
			 range of diseases and disabilities including diabetes, spinal cord injury,
			 heart disease, stroke, and various forms of cancer.</text>
			</paragraph>
      <paragraph id="H0239B821845B4C1DB4A32DFCEF697586">
        <enum>(3)</enum>
        <text>A United States national strategy on regenerative medicine is critical to ensure that this
			 technology fulfills its potential to cure and treat diseases and
			 disabilities, reduce overall health spending, and promote economic growth.</text>
			</paragraph>
      <paragraph id="H8355D76FD3184F388FAFEFA28FC1F017">
        <enum>(4)</enum>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="9700" entity-type="federal-body">Department of Defense</cato:entity-ref> has stated that regenerative medicine has the potential to treat many
			 battlefield injuries such as burns, that it has the potential to heal
			 wounds without scarring, and that it has the potential to be used for
			 traumatic brain injury and other forms of trauma, craniofacial
			 reconstruction, limb reconstruction, regeneration, and transplantation.</text>
			</paragraph>
      <paragraph id="H8FC5F000BAF74A94A1D7B355AB9EDD36">
        <enum>(5)</enum>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Department of Health and Human Services</cato:entity-ref> and the Multi-Agency Tissue Engineering Science
			 Interagency Working Group have endorsed a national initiative to support
			 research and product development in regenerative medicine.</text>
			</paragraph>
      <paragraph id="H943001EDBE5E44AC8149AC59F2AE892E">
        <enum>(6)</enum>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Department of Health and Human Services</cato:entity-ref> has said the potential benefits of regenerative
			 medicine in improved health care and economic savings are enormous. States
			 that have invested in regenerative medicine have experienced economic
			 growth and see future growth potential, including an increase in biotech
			 employment, payroll increases, and proportional impacts on tax receipts.</text>
			</paragraph>
    </section>
    <section id="H4CA54209D99A4FC69A00AAF960A80027">
      <enum>3.</enum>
      <header>Report on ongoing Federal programs and activities regarding regenerative medicine</header>
      <text display-inline="no-display-inline">Not later than 180 days after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="0500" entity-type="federal-body">Comptroller General of the
			 United States</cato:entity-ref> shall provide for the completion, and submission to the
			 Congress, of a report identifying all ongoing Federal programs and
			 activities regarding regenerative medicine.</text>
		</section>
    <section id="H929EFFD38A094CD0AD2C9A7FB68CC33D">
      <enum>4.</enum>
      <header>Establishment of Regenerative Medicine Coordinating Council</header>
			<subsection id="HE8FA86365887412292146A7E1A71B3C2">
        <enum>(a)</enum>
        <header>Establishment</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref> shall establish, within six months of the enactment of
			 this Act, in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="750S">Office of the Secretary</cato:entity-ref>, a <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Regenerative Medicine
			 Coordinating Council</cato:entity-ref> (in this section referred to as the <quote>Council</quote>).</text>
			</subsection>
      <subsection id="HB7F3D6583A6D499E9076D5991B256D69">
        <enum>(b)</enum>
        <header>Composition</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Council</cato:entity-ref> shall be composed of the following:</text>
				<paragraph id="H3AF7D23591F344EB97D3684ABC161B48">
          <enum>(1)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1300" entity-type="federal-body">Secretary of Commerce</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="H4630F7D3F9AE414AA8206C1F9DF90361">
          <enum>(2)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="9700" entity-type="federal-body">Secretary of Defense</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="H2055EEE218B241FC8DEC7779AB24422A">
          <enum>(3)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="H0528A7B8A50B42E9935B2CEEF29AB5FA">
          <enum>(4)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="2000" entity-type="federal-body">Secretary of the Treasury</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="H1512137F87454D6C83E3DFC0AF3156A3">
          <enum>(5)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="3600" entity-type="federal-body">Secretary of Veterans Affairs</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="HDF4457CDFC914EA89A9A83BF9CAB778E">
          <enum>(6)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7528">Administrator of the Agency for Healthcare Research and Quality</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="H23E137E7774540EA95EB489183BB9586">
          <enum>(7)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7530" entity-type="federal-body">Administrator of the Centers for Medicare &amp; Medicaid Services</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="HF5974A0FAF224F8EA331530E92947C0F">
          <enum>(8)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Commissioner of Food and Drugs</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="HB628D48ED9F841DDB959B450BC692DE1">
          <enum>(9)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">Director of the National Institutes of Health</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="H172B0E257353420D8A57AE57E2B7EFDC">
          <enum>(10)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1341">Director of the National Institutes of Standards and Technology</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="H1E95E43A6D4B47A4BF88B3056D0A18FC">
          <enum>(11)</enum>
          <text>The members appointed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Regenerative Medicine Promotion Act of 2014/s:4/ss:d" proposed="true">subsection (d)</cato:entity-ref>.</text>
				</paragraph>
      </subsection>
      <subsection id="HCFD63125B44E424BB04BD355A8CA7654">
        <enum>(c)</enum>
        <header>Chair</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref> shall be the Chair of the Council.</text>
			</subsection>
      <subsection id="H0A8D01C4F5814B39BC0D70ADA86569E4">
        <enum>(d)</enum>
        <header>Members appointed by secretary</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall appoint at least 5 persons to serve as members of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Council</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Regenerative Medicine Promotion Act of 2014/s:4/ss:b/p:11" proposed="true">subsection
			 (b)(11)</cato:entity-ref>. The members of the Council appointed under the preceding sentence
			 shall include persons with expertise in third-party payment, regenerative
			 medicine researchers from academic institutions, patient advocates,
			 persons with expertise in drug discovery, persons with expertise in drug
			 development, persons with expertise in basic research, persons with
			 expertise in translational research, persons with expertise in medical
			 device development, persons with expertise in biomaterials, clinicians,
			 and persons with expertise in clinical research.</text>
			</subsection>
      <subsection id="H6000268E8A1B43A48D95508A724E8DFB">
        <enum>(e)</enum>
        <header>Functions</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Council</cato:entity-ref> shall—</text>
				<paragraph id="HA63C42F51B2E4EB1BF3D03C1D22A33AA">
          <enum>(1)</enum>
          <text>consult with, and provide information to, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref> for purposes
			 of implementing any recommendations in the report required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Regenerative Medicine Promotion Act of 2014/s:3" proposed="true">section 3</cato:entity-ref>;</text>
				</paragraph>
        <paragraph id="H155A9A73DF8A4FC98406EECB995705C5">
          <enum>(2)</enum>
          <text>prepare, and keep up-to-date, a national strategy to support research into regenerative medicine
			 and the development of drugs, biological products, medical devices, and
			 biomaterials for use in regenerative medicine;</text>
				</paragraph>
        <paragraph id="H9473F7BB3B6D4B0C88ADAA8FD55F2F85">
          <enum>(3)</enum>
          <text>prepare a plan specifying priorities for research into regenerative medicine;</text>
				</paragraph>
        <paragraph id="H1B3A0D5AC7074A05998804AD1A932E50">
          <enum>(4)</enum>
          <text>not later than 1 year after the date of the enactment of this Act, establish priorities for the
			 award of grants under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Regenerative Medicine Promotion Act of 2014/s:5" proposed="true">sections 5</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Regenerative Medicine Promotion Act of 2014/s:6" proposed="true">6</cato:entity-ref> (relating to grants for basic or
			 preclinical research into regenerative medicine and for development of
			 drugs, biological products, medical devices, and biomaterials for use in
			 regenerative medicine, respectively);</text>
				</paragraph>
        <paragraph id="HF1C97579A3AD41DB9518525BACDD0B99">
          <enum>(5)</enum>
          <text>identify sources of funding for research into regenerative medicine;</text>
				</paragraph>
        <paragraph id="HC6A852A84CEA413AA19C5388862B2856">
          <enum>(6)</enum>
          <text>identify areas where such funding is inadequate;</text>
				</paragraph>
        <paragraph id="H72B3BC57FF4041A582B38B2D7A837744">
          <enum>(7)</enum>
          <text>make recommendations regarding Federal regulatory, reimbursement, tax, and other policies that will
			 support development and marketing of regenerative medicine products;</text>
				</paragraph>
        <paragraph id="H6F9A2C0105614A889B4C8B7420E9415C">
          <enum>(8)</enum>
          <text>facilitate development of consensus standards regarding scientific issues critical to regulatory
			 approval of regenerative medicine products; and</text>
				</paragraph>
        <paragraph id="H0F679ACDBDB14594BD59186B68105178">
          <enum>(9)</enum>
          <text>determine the need for establishing centers of excellence or consortia to further advance
			 regenerative medicine.</text>
				</paragraph>
      </subsection>
      <subsection id="H43106B158016484895AAF71CB27A9FF6">
        <enum>(f)</enum>
        <header>Transparency; reporting requirements</header>
				<paragraph id="H53F1E434C2D047B4A57E690BBBAFF190">
          <enum>(1)</enum>
          <header>Transparency</header>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Council</cato:entity-ref> shall adopt procedures to ensure the receipt of public input, such as holding public
			 stakeholder meetings or creating advisory boards.</text>
				</paragraph>
        <paragraph id="H917E6FB260C440FF9FA292F27C3F2618">
          <enum>(2)</enum>
          <header>Annual reports</header>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Council</cato:entity-ref> shall submit an annual report on its activities to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">Director of the
			 National Institutes of Health</cato:entity-ref>, and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Commissioner of Food and Drugs</cato:entity-ref>.
			 Each such report shall—</text>
					<subparagraph id="H7F981033CB82490AB2B2822972FFD9AF">
            <enum>(A)</enum>
            <text>provide details on progress in meeting goals identified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Council</cato:entity-ref> for regenerative medicine;</text>
					</subparagraph>
          <subparagraph id="HB90ED02B4B714F98AC6D7DD6E85804FE">
            <enum>(B)</enum>
            <text>make recommendations regarding funding, regulatory, or other policies to achieve regenerative
			 medicine goals identified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Council</cato:entity-ref>;</text>
					</subparagraph>
          <subparagraph id="HCCD6EDEA1104439C8A41FAD7A8E6B7AE">
            <enum>(C)</enum>
            <text>identify all regenerative medicine products currently on the market and those in development;</text>
					</subparagraph>
          <subparagraph id="H2B61E23B432D44E0AFB27E00FE0D1B1C">
            <enum>(D)</enum>
            <text>identify regenerative medicine research and technological advances and discoveries that occurred in
			 the previous year; and</text>
					</subparagraph>
          <subparagraph id="H9EE4300BCF6D487F99DEEF3AB1C577FF">
            <enum>(E)</enum>
            <text>assess the impact of regenerative medicine on the Nation’s economy, including with respect to—</text>
						<clause id="H506AD8FEE8CB4799AFE82DE550080B57">
              <enum>(i)</enum>
              <text>the number of people employed in companies or research institutions working in regenerative
			 medicine;</text>
						</clause>
            <clause id="H243BBD29D8AD4F41A84A208062019AD4">
              <enum>(ii)</enum>
              <text>the number of companies pursuing regenerative medicine products;</text>
						</clause>
            <clause id="H13BC943E8EA246B68E4CFE485C019A06">
              <enum>(iii)</enum>
              <text>increases in tax revenues; and</text>
						</clause>
            <clause id="HAEB646DDCDFA4111B7DB2AFAD1C5EC9B">
              <enum>(iv)</enum>
              <text>the impact on national health spending.</text>
						</clause>
          </subparagraph>
        </paragraph>
      </subsection>
    </section>
    <section id="H1E896A123DE44DCFA432F5BEFEBAFEB0">
      <enum>5.</enum>
      <header>Grants for basic or preclinical research into regenerative medicine</header>
			<subsection id="H1DAA5AF041D249D99FD49CF520EF90F9">
        <enum>(a)</enum>
        <header>Grants for basic or preclinical research</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may make grants to eligible entities for the purpose of funding basic or preclinical
			 research into regenerative medicine.</text>
			</subsection>
      <subsection id="H03BF9B4E837A49E78C37F4413FB45E22">
        <enum>(b)</enum>
        <header>Conditions</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may make a grant under this section for research only if—</text>
				<paragraph id="H0BF3EA089D694E60B4EAF50C3D88B2F1">
          <enum>(1)</enum>
          <text>the research is carried out directly by the grant recipient;</text>
				</paragraph>
        <paragraph id="HB0B48BDD516A42ADAB80EAB96A37F970">
          <enum>(2)</enum>
          <text>the research is partly funded by one or more private entities; and</text>
				</paragraph>
        <paragraph id="HF48C52CA08E54F65B488616F2DE8C55C">
          <enum>(3)</enum>
          <text>the amount of the grant does not exceed the total amount provided for the research by private
			 entities (other than the grant recipient itself).</text>
				</paragraph>
      </subsection>
      <subsection id="HB16626E738B84710A1C072E09342FD44">
        <enum>(c)</enum>
        <header>Terms and conditions</header>
        <text>A grant under this section may be made on such terms and conditions as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines
			 appropriate.</text>
			</subsection>
      <subsection id="H67568DCEEFDE4BAC87B36ED98B2A99CF">
        <enum>(d)</enum>
        <header>Priority</header>
        <text>In awarding grants under this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall take into consideration the priorities
			 established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Regenerative Medicine Coordinating Council</cato:entity-ref> under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Regenerative Medicine Promotion Act of 2014/s:4/ss:e" proposed="true">section 4(e)</cato:entity-ref>.</text>
			</subsection>
      <subsection id="H507D4CB7463E4149B793F25219D05D47">
        <enum>(e)</enum>
        <header>Definitions</header>
        <text>In this section:</text>
				<paragraph id="H72F96C1C92704A9CBACDA05A3F90C6A8">
          <enum>(1)</enum>
          <text>The term <quote>eligible entity</quote> means a nonprofit entity or an institution of higher education.</text>
				</paragraph>
        <paragraph id="H3FE0763D8CEE4EB6A94AFBA705EB3D08">
          <enum>(2)</enum>
          <text>The term <quote>institution of higher education</quote> has the meaning given that term in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Higher Education Act of 1965/s:101">section 101 of the Higher Education Act of 1965</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/20/1001">20 U.S.C.
			 1001</cato:entity-ref>)</cato:entity>.</text>
				</paragraph>
        <paragraph id="H952EA0866E4C4DF0AB30FB7B5B4479E5">
          <enum>(3)</enum>
          <text>The term <quote>nonprofit entity</quote> means an entity that—</text>
					<subparagraph id="H49B8DA122A5845998B6D6E9CB746334A">
            <enum>(A)</enum>
            <text>is described in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Internal Revenue Code of 1986/s:501/ss:c/p:3">
                  <external-xref legal-doc="usc" parsable-cite="usc/26/501">section 501(c)(3)</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/26/501">
                <cato:entity-ref entity-type="uscode" value="usc/26/501/c/3">26 U.S.C. 501(c)(3)</cato:entity-ref>
              </external-xref>)</cato:entity>; and</text>
					</subparagraph>
          <subparagraph id="HA63A3E3533254B9A95DE0D83A3EE4CFE">
            <enum>(B)</enum>
            <text>is exempt from tax under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Internal Revenue Code of 1986/s:501/ss:a">
                  <external-xref legal-doc="usc" parsable-cite="usc/26/501">section 501(a)</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/26/501">
                <cato:entity-ref entity-type="uscode" value="usc/26/501/a">26 U.S.C. 501(a)</cato:entity-ref>
              </external-xref>)</cato:entity>.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H0B00331ECF7947E7B21F26C0175F6704">
          <enum>(4)</enum>
          <text>The term <quote>Secretary</quote> means the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">Director of the National
			 Institutes of Health</cato:entity-ref>.</text>
				</paragraph>
      </subsection>
    </section>
    <section id="HF8889E1FCC364DF2AC7C5688D87FF3BF">
      <enum>6.</enum>
      <header>Grants for development of drugs, biological products, medical devices, and biomaterials for use in
			 regenerative medicine</header>
			<subsection id="HDF0581B3495246C4BB2F73CDF4D6477C">
        <enum>(a)</enum>
        <header>Grants for drug development</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may make grants to eligible entities for the purpose of funding projects that have as
			 their aim—</text>
				<paragraph id="HEBE3203B24A543E1B976D6A2462A40B1">
          <enum>(1)</enum>
          <text>the research and development of drugs, biological products, medical devices, and biomaterials for
			 use in regenerative medicine; and</text>
				</paragraph>
        <paragraph id="HBA600425FF7B4D8FB66A207B2C185C2D">
          <enum>(2)</enum>
          <text>the making of an investigational new drug application with respect to such drugs or biological
			 products, or the making of an investigational device exemption application
			 with respect to such devices, by not later than the end of the 4-year
			 period beginning on the date on which such grant is made.</text>
				</paragraph>
      </subsection>
      <subsection id="H5FD2AFE97C294380B434FBBCA0892CC9">
        <enum>(b)</enum>
        <header>Terms and conditions</header>
        <text>A grant under this section may be made on such terms and conditions as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines
			 appropriate.</text>
			</subsection>
      <subsection id="HFC8CA5163F9143F6B18C4053B676D6FF">
        <enum>(c)</enum>
        <header>Priority</header>
        <text>In awarding grants under this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall take into consideration the priorities
			 established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Regenerative Medicine Coordinating Council</cato:entity-ref> under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Regenerative Medicine Promotion Act of 2014/s:4/ss:e" proposed="true">section 4(e)</cato:entity-ref>.</text>
			</subsection>
      <subsection id="HFCD464C8F5DA41808193077DC5CE64BD">
        <enum>(d)</enum>
        <header>Definitions</header>
        <text>In this section:</text>
				<paragraph id="H46D2D8D1BA84417A93D598804BBBDFED">
          <enum>(1)</enum>
          <text>The term <quote>biological product</quote> has the meaning given the term in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Public Health Service Act/s:351/ss:i">section 351(i) of the Public Health Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/262/i">42 U.S.C.
			 262(i)</cato:entity-ref>)</cato:entity>.</text>
				</paragraph>
        <paragraph id="HDCFE43F4D59247DFB030856D3ACED64F">
          <enum>(2)</enum>
          <text>The terms <quote>drug</quote> and <quote>medical device</quote> have the meanings given to the terms <quote>drug</quote> and <quote>device</quote>, respectively, in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:201">section 201 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/321">
              <cato:entity-ref entity-type="uscode" value="usc/21/321">21 U.S.C. 321</cato:entity-ref>
            </external-xref>)</cato:entity>.</text>
				</paragraph>
        <paragraph id="H4017EF0E8E7F4F35BD1D04CA563AB90A">
          <enum>(3)</enum>
          <text>The term <quote>eligible entity</quote> means a collaborative partnership including—</text>
					<subparagraph id="HE9D1E95222CA497FAFA26422935B082D">
            <enum>(A)</enum>
            <text>a qualified nonprofit entity or an institution of higher education; and</text>
					</subparagraph>
          <subparagraph id="HD90901E71A8A45CBBC0FEED8D8293B38">
            <enum>(B)</enum>
            <text>a for-profit entity.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H3A346BD0CD0947ADAEBF9E84EA7B3F2E">
          <enum>(4)</enum>
          <text>The term <quote>institution of higher education</quote> has the meaning given that term in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Higher Education Act of 1965/s:101">section 101 of the Higher Education Act of 1965</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/20/1001">20 U.S.C.
			 1001</cato:entity-ref>)</cato:entity>.</text>
				</paragraph>
        <paragraph id="H09683E72932948D2B8C769A09686CEC4">
          <enum>(5)</enum>
          <text>The term <quote>investigational new drug application</quote> means an investigational new drug application that is made to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Food and Drug Administration</cato:entity-ref>
			 under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">section 505(i) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/505/i">21
			 U.S.C. 505(i)</cato:entity-ref>)</cato:entity>.</text>
				</paragraph>
        <paragraph id="H286FC8F903F64BD5971BC9164B83C792">
          <enum>(6)</enum>
          <text>The term <quote>investigational device exemption application</quote> means an application for an investigational device exemption that is made to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Food and Drug
			 Administration</cato:entity-ref> under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:520/ss:g">section 520(g) of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/360j">
              <cato:entity-ref entity-type="uscode" value="usc/21/360j/g">21 U.S.C. 360j(g)</cato:entity-ref>
            </external-xref>)</cato:entity>.</text>
				</paragraph>
        <paragraph id="H6633405CB2B94A5687025706F37DA4CA">
          <enum>(7)</enum>
          <text>The term <quote>qualified nonprofit entity</quote> means an entity that—</text>
					<subparagraph id="HE43D1BC1EC934C4A8918CF156AE325F5">
            <enum>(A)</enum>
            <text>is described in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Internal Revenue Code of 1986/s:501/ss:c/p:3">
                  <external-xref legal-doc="usc" parsable-cite="usc/26/501">section 501(c)(3)</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/26/501">
                <cato:entity-ref entity-type="uscode" value="usc/26/501/c/3">26 U.S.C. 501(c)(3)</cato:entity-ref>
              </external-xref>)</cato:entity>; and</text>
					</subparagraph>
          <subparagraph id="H013D530B2E3848ABA97CA49D1F25525C">
            <enum>(B)</enum>
            <text>is exempt from tax under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Internal Revenue Code of 1986/s:501/ss:a">
                  <external-xref legal-doc="usc" parsable-cite="usc/26/501">section 501(a)</external-xref> of the Internal Revenue Code of 1986</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/26/501">
                <cato:entity-ref entity-type="uscode" value="usc/26/501/a">26 U.S.C. 501(a)</cato:entity-ref>
              </external-xref>)</cato:entity>.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="H8A859A2A33804BF496E762A703FE6A74">
          <enum>(8)</enum>
          <text>The term <quote>Secretary</quote> means the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">Director of the National
			 Institutes of Health</cato:entity-ref>.</text>
				</paragraph>
      </subsection>
    </section>
    <section id="HBD6A79CC31584D5BB62A3DB046B1AD4D">
      <enum>7.</enum>
      <header>Supporting innovation in regenerative medicine through cures acceleration network</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/s:480">Section 480 of the Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/287a">
          <cato:entity-ref entity-type="uscode" value="usc/42/287a">42 U.S.C. 287a</cato:entity-ref>
        </external-xref>)</cato:entity> is amended—</text>
			<paragraph id="HF2D3CC72D8884183AA5B12A357ABCFBC">
        <enum>(1)</enum>
        <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:480/ss:d">subsection (d)</cato:entity-ref>, by adding at the end the following:</text>
				<quoted-block id="H4554D6BCECEB4784BF9174BF04473BC5" style="OLC">
					<paragraph id="HF44B0F02A4F64C5588EEDC99808B7865">
            <enum>(7)</enum>
            <header>Collaboration</header>
            <text>With respect to activities of the Board relating to medical products and behavioral therapies for
			 use in regenerative medicine, the Board shall collaborate with the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Regenerative Medicine Coordinating Council" entity-parent-id="750S" proposed="true">Regenerative Medicine Coordinating Council</cato:entity-ref>.</text>
          </paragraph>
          <after-quoted-block>; and</after-quoted-block>
        </quoted-block>
			</paragraph>
      <paragraph id="HCB7A293367A5479EBD64F112DCAA9D18">
        <enum>(2)</enum>
        <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:480/ss:e/p:3">subsection (e)(3)</cato:entity-ref>, by adding at the end the following:</text>
				<quoted-block id="HBCA68A34F9D543FDB93AC8946DE0886D" style="OLC">
					<subparagraph id="H0C63599AD6D745F2BA5A21E4AA697CB4">
            <enum>(D)</enum>
            <header>The cures acceleration awards with respect to products and therapies for use in regenerative
			 medicine</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">Director of NIH</cato:entity-ref> may, without regard to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:480/ss:e/p:3/sp:A">subparagraphs (A)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:480/ss:e/p:3/sp:B">(B)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:480/ss:e/p:3/sp:C">(C)</cato:entity-ref>, provide assistance
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:480/ss:e/p:1">paragraph (1)</cato:entity-ref> with respect to medical products and behavioral
			 therapies for use in regenerative medicine, including assistance—</text>
						<clause id="H0CA0EE0E8E7D4773906AC1D125FCFBB4">
              <enum>(i)</enum>
              <text>to perform clinical trials under a protocol approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Commissioner of Food and Drugs</cato:entity-ref> or
			 studies which use good manufacturing practice or good laboratory practice
			 procedures and the data from which are intended for inclusion in an
			 investigational new drug application or an investigational device
			 exemption application; or</text>
						</clause>
            <clause id="H42D6499B262D4499B9456881B56B3E5B">
              <enum>(ii)</enum>
              <text>to perform basic research or preclinical studies in regenerative medicine the data from which are
			 not intended for inclusion in an investigational new drug application or
			 an investigational device exemption application.</text>
            </clause>
          </subparagraph>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</paragraph>
    </section>
    <section id="H04247BCD794341439A28BE6726202C7A">
      <enum>8.</enum>
      <header>Funding for Food and Drug Administration research</header>
			<subsection id="HE89D89CAF174447AA3B7CE6F4980C165">
        <enum>(a)</enum>
        <header>Grants</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may—</text>
				<paragraph id="H64B8C97D85BB417B90498A609A1DC7A0">
          <enum>(1)</enum>
          <text>conduct, support, or collaborate in regulatory research for the purpose of assisting the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Food and
			 Drug Administration</cato:entity-ref> to perform its functions with respect to regenerative
			 medicine; or</text>
				</paragraph>
        <paragraph id="H4004B036D3FC463FA07A48F236816051">
          <enum>(2)</enum>
          <text>make grants to fund regulatory research for such purpose.</text>
				</paragraph>
      </subsection>
      <subsection id="HDF3FDE00AB564CCE88013A9FDE8C3C62">
        <enum>(b)</enum>
        <header>Definitions</header>
        <text>In this section:</text>
				<paragraph id="H43A0CA5A93BD4D7688A2557CE926C785">
          <enum>(1)</enum>
          <text>The term <quote>regulatory research</quote> means research regarding development, evaluation, and availability of new or improved tools,
			 methods, standards, and applied science that support a better
			 understanding and improved evaluation of product safety, quality,
			 effectiveness, and manufacturing throughout the product life cycle.</text>
				</paragraph>
        <paragraph id="HE9EBDE1E44DB4023A61E0EEB03BB0745">
          <enum>(2)</enum>
          <text>The term <quote>Secretary</quote> means the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Commissioner of Food and
			 Drugs</cato:entity-ref>.</text>
				</paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>